

Speaker	Session Title	Date	Location	Individual's Role(s) in Activity	Nature of relationship to ineligible company
Maureen Okam Achebe, MD, MPH	Updates on Current, Emerging and Curative Therapies for Sickle Cell Disease	January 10 - 11, 2025	New York, NY	Speaker	<b>Consultancy:</b> Vertex Pharmaceuticals <b>Membership on a Board or Advisory Committee:</b> Global Blood Therapeutics, Pharmacosmos, Shield Therapeutics, Vertex Pharmaceuticals
Susan Bal, MD	Innovations in Multiple Myeloma and Plasma Cell Dyscrasias: Charting the Path Forward	January 10 - 11, 2025	New York, NY	Speaker	<b>Consultancy:</b> AbbVie, AstraZeneca, Bristol Myers Squibb, Janssen, Pfizer <b>Research Funding:</b> AbbVie, BeiGene, Bristol Myers Squibb, Fate Therapeutics <b>Honoraria:</b> Adaptive Biotechnology
Paul Barr, MD	Highlights in Aggressive and Hodgkin Lymphomas	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Consultancy:</b> AbbVie, Adaptive Therapeutics, AstraZeneca, Beigene, Bristol Myers Squibb, Genentech, Gilead, Janssen, Morphosys, Seattle Genetics, TG Therapeutics <b>Research Funding:</b> AbbVie, AstraZeneca, TG Therapeutics <b>Membership on a Board or Advisory Committee:</b> TG Therapeutics
Tyler Buckner, MD, MSc	Inherited Disorders of Coagulation	January 10 - 11, 2025	Seattle, WA	Planner/Speaker	<b>Consultancy:</b> BioMarin (ended 8/16/2023) <b>Honoraria:</b> Novo Nordisk (ended 4/1/2023), Octapharma (ended 12/9/2022), Sanofi (ended 7/11/2024)
Patrick Burke, MD	ALL Updates from ASH: First line targeted therapy in Ph- and Ph+ ALL and a new CAR-T!	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Consultancy:</b> Servier
Cecelia Calhoun, MD, MPHS, MBA	Updates on Current, Emerging and Curative Therapies for Sickle Cell Disease	January 10 - 11, 2025 January 17- 18, 2025	Seattle, WA Chicago, IL	Speaker	<b>Consultancy:</b> CVS Caremark, Sanius Health <b>Membership on a Board or Advisory Committee:</b> BlueBird Bio
Carla Casulo, MD	Highlights in Aggressive and Hodgkin Lymphomas	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Consultancy:</b> AbbVie, BMS, Genentech, Genmab <b>Honoraria:</b> AbbVie, BMS, Genentech <b>Membership on a Board or Advisory Committee:</b> Genentech <b>Research Funding:</b> Genentech
Alexey Danilov, MD, PhD	The Evolving Role of Targeted and Immunotherapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Consultancy:</b> AbbVie, AstraZeneca, Beigene, Bristol Meyers Squibb, Genentech, Incyte, Lilly Oncology, MEI, Merck, Morphosys, Nurix, Pharmacyclics, Regeneron <b>Research Funding:</b> AbbVie, AstraZeneca, Bayer, Beigene, Bristol Meyers Squibb, Cyclacel, Genentech, Lilly Oncology, MEI, Merck, Nurix, Regeneron, SecuraBio, Takeda Oncology
Courtney D. DiNardo, MD	Acute Myeloid Leukemia	January 31 - February 1, 2025	Washington, DC	Speaker	<b>Consultancy:</b> AbbVie, AstraZeneca, BMS, Cleave, Schrodinger, Servier <b>Research Funding:</b> Astex, BMS, Celgene, Cleave, Daiichi Sankyo, Foghorn, Loxo, Schrodinger, Servier <b>Honoraria:</b> Astellas, Celgene, Daiichi Sankyo, GSK, Loxo, Servier <b>Membership on a Board or Advisory Committee:</b> Abbvie, AstraZeneca, GenMab, GSK, Servier
Adam Duvall, MD	ALL Updates from ASH: First line targeted therapy in Ph- and Ph+ ALL and a new CAR-T!	January 17- 18, 2025	Chicago, IL	Speaker	<b>Consultancy:</b> Novartis, Sago Marketing
Pamela Egan, MD	Clinical Applications of Health Outcomes Research for Blood Cancers	January 31 - February 1, 2025	Washington, DC	Planner/Speaker	Nothing to disclose.
Areej El-Jawahri, MD	Clinical Applications of Health Outcomes Research for Blood Cancers	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Consultancy:</b> Incyte Corporation, Novartis
Patrick Ellsworth, MD	Inherited Disorders of Coagulation	January 10 - 11, 2025 January 17- 18, 2025	New York, NY Chicago, IL	Speaker	<b>Consultancy:</b> Genentech <b>Research Funding:</b> Novo Nordisk
Charles Foucar, MD	Acute Myeloid Leukemia	January 17- 18, 2025	Chicago, IL	Speaker	<b>Consultancy:</b> Stemline <b>Honoraria:</b> Binaytara <b>Research Funding:</b> Novartis
Guillermo Garcia-Manero, MD	Myelodysplastic Syndromes and Clonal Hematopoiesis	January 17- 18, 2025	Chicago, IL	Speaker	<b>Research Funding:</b> AbbVie, Ascentage, Astex, BMS, Chordia, Curis, Eisai, Genentech, Kurome, Merck, Novartis, Rigel, Servier
Doris Hansen, MD	Innovations in Multiple Myeloma and Plasma Cell Dyscrasias: Charting the Path Forward	January 17- 18, 2025	Chicago, IL	Speaker	<b>Consultancy:</b> BMS, Janssen, Karyopharm Therapeutics, Kite Pharma, Legend Biotech, Pfizer <b>Research Funding:</b> Adaptive Biotechnologies, BMS, Karyopharm Therapeutics <b>Membership on a Board or Advisory Committee:</b> BMS, Janssen
Chi-Joan How, MD	Moving the Needle in the Treatment of Myeloproliferative Neoplasms and Chronic Myeloid Leukemia	January 31 - February 1, 2025	Washington, DC	Speaker	<b>Consultancy:</b> PharmaEssentia, Merck
Cyrus Hsia, MD, FRCPC	Consultative Hematology: What Are My Other Options?	January 10 - 11, 2025	New York, NY	Speaker	<b>Honoraria:</b> Amgen, BMS, Medison, Novartis, Pfizer, Sobi <b>Speakers Bureau:</b> Amgen, BMS, Medison, Novartis, Pfizer, Sobi <b>Consultancy:</b> Sobi
Morgan Jones, MD, PhD	Myelodysplastic Syndromes and Clonal Hematopoiesis	January 10 - 11, 2025 January 31 - February 1, 2025	New York, NY Washington, DC	Speaker	Nothing to disclose.

Speaker	Session Title	Date	Location	Individual's Role(s) in Activity	Nature of relationship to ineligible company
Manali Kamdar, MD, MBBS	Highlights in Aggressive and Hodgkin Lymphomas	January 31 - February 1, 2025	Washington, DC	Speaker	<b>Consultancy:</b> Adaptive Biotechnologies, AbbVie, ADC Therapeutics, Aztrazeneca, Beigene, BMS, Kite, Syncopation <b>Membership on a Board or Advisory Committee:</b> Celgene, Genentech <b>Research Funding:</b> Genentech, Novartis
Jonathan Kaufman, MD	Innovations in Multiple Myeloma and Plasma Cell Dyscrasias: Charting the Path Forward	January 10 - 11, 2025	Seattle, WA Washington, DC	Planner/Speaker	<b>Consultancy:</b> AbbVie, BMS, Sanofi, Sebia <b>Membership on a Board or Advisory Committee:</b> Incyte
Andrew Kuykendall, MD	Moving the Needle in the Treatment of Myeloproliferative Neoplasms and Chronic Myeloid Leukemia	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Consultancy:</b> AbbVie, Blueprint Medicines, Geron, Incyte, Morphosys/Constellation, Protagonist, Sierra Oncology <b>Honoraria:</b> AbbVie, Blueprint Medicines, Cogent, CTI Biopharma, Morphosys/Constellation, Novartis, PharmaEssentia, Sierra Oncology <b>Speakers Bureau:</b> Blueprint Medicines <b>Research Funding:</b> Blueprint Medicines, Celgene/BMS, Janssen, Morphosys/Constellation, Novartis, Prelude, Protagonist, Sierra Oncology
Catherine Lai, MD, MPH	Acute Myeloid Leukemia	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Consultancy:</b> AbbVie, Astellas, Bristol Myers Squibb, Daiichi, Genentech, Jazz Pharma, MacroGenics, Novartis, PDS, Pfizer, Rigel, Servier, Syndax, Taiho <b>Research Funding:</b> Jazz Pharma
Thomas LeBlanc, MD, MA, MHS	Clinical Applications of Health Outcomes Research for Blood Cancers	January 10 - 11, 2025 January 17- 18, 2025	New York, NY Chicago, IL	Speaker	<b>Consultancy:</b> AbbVie, Apellis, BMS, Celgene, DoseNtrix, Genentech, GSK, Lilly, Menarini Stemline, Novartis, Pfizer, Rigel <b>Honoraria:</b> AbbVie, Astellas, Celgene, Janssen, Jazz, Rigel <b>Speakers Bureau:</b> AbbVie, Agios/Servier, BMS, Celgene, Incyte, Jazz, Rigel <b>Research Funding:</b> AstraZeneca, BMS, Deverra Therapeutics, Jazz <b>Membership on a Board or Advisory Committee:</b> Genentech <b>Stock Options (Private Company):</b> DoseNtrix
Grace Lee, MD	Transfusion Medicine	January 17- 18, 2025	Chicago, IL	Speaker	<b>Research Funding:</b> Gilead, Novartis, Sanofi, Zymeron
Ryan Mattison, MD	ALL Updates from ASH: First line targeted therapy in Ph- and Ph+ ALL and a new CAR-T!	January 10 - 11, 2025 January 31 - February 1, 2025	New York, NY Washington, DC	Speaker	<b>Membership on a Board or Advisory Committee:</b> Nkarta
Rakhi Naik, MD, MS	Updates on Current, Emerging and Curative Therapies for Sickle Cell Disease	January 31 - February 1, 2025	Washington, DC	Planner/Speaker	<b>Consultancy:</b> 23andMe, Elsevier <b>Research Funding:</b> Rigel
Sarah O'Brien, MD, MSc	A Day in the Life of a Shematologist: Exploring the Intersection of Hematology and Women's Health	January 10 - 11, 2025 January 31 - February 1, 2025	New York, NY Washington, DC	Speaker	<b>Membership on a Board or Advisory Committee:</b> AstraZeneca, Avana, Bristol Myers Squibb, iECURE, Pediatric BMS Advisory Board, Apixaban, Pharmacosmos
Afaf Osman, MD	Myelodysplastic Syndromes and Clonal Hematopoiesis	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Research Funding:</b> SYROS
Menaka Pai, MD, FRCPC	A Day in the Life of a Shematologist: Exploring the Intersection of Hematology and Women's Health	January 17- 18, 2025	Chicago, IL	Speaker	<b>Honoraria:</b> Pfizer
Katerina Pavenski, MD, MSc, FRCPC	Transfusion Medicine	January 10 - 11, 2025 January 31 - February 1, 2025	Seattle, WA Washington, DC	Speaker	<b>Honoraria:</b> Octapharma <b>Research Funding:</b> Roche, Sanofi, SOBI, Takeda
Kristen Pettit, MD	Moving the Needle in the Treatment of Myeloproliferative Neoplasms and Chronic Myeloid Leukemia	January 17- 18, 2025	Chicago, IL	Planner/Speaker	<b>Membership on a Board or Advisory Committee:</b> AbbVie, CTI Biopharma, Incyte, PharmaEssentia, Sierra oncology <b>Research Funding:</b> AbbVie, Blueprint biomedicines, CTI Biopharma, Imago Biosciences, Kura Oncology, Macrognetics, PharmaEssentia, Protagonist
Jacquelyn Powers, MD, MS	Consultative Hematology: What Are My Other Options?	January 17- 18, 2025	Chicago, IL	Speaker	<b>Membership on a Board or Advisory Committee:</b> Pharmacosmos LLC, Women's Health Research Collaborative / The Kinetix Group
Jerald Radich, MD	Acute Myeloid Leukemia	January 31 - February 1, 2025	Washington, DC	Speaker	<b>Consultancy:</b> Ariad, BMS, Novartis, Pfizer <b>Honoraria:</b> Novartis <b>Research Funding:</b> Novartis
Ran Reshef, MD, MSc	Classical Insights in Transplantation	January 10 - 11, 2025	New York, NY	Speaker	<b>Consultancy:</b> Allogene, Autolus, Bayer, CareDx, Gilead Sciences, Incyte, Orca Bio, Sana Biotechnology, TScan <b>Research Funding:</b> AbbVie, BMS, Allogene, Autolus, Bayer, Genentech, Gilead Sciences, Janssen
Jia Ruan, MD, PhD	The Evolving Role of Targeted and Immunotherapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia	January 10 - 11, 2025 January 31 - February 1, 2025	New York, NY Washington, DC	Planner/Speaker	<b>Consultancy:</b> AstraZeneca, BMS, Daiichi Sankyo, Kite Pharma, Seagen <b>Research Funding:</b> AstraZeneca, BMS, Daiichi Sankyo, Genentech

Speaker	Session Title	Date	Location	Individual's Role(s) in Activity	Nature of relationship to ineligible company
Sarah Rutherford, MD	Highlights in Aggressive and Hodgkin Lymphomas	January 10 - 11, 2025	New York, NY	Speaker	<b>Consultancy:</b> ADC Therapeutics, BMS, GenMab, Karyopharm, Kite, Pfizer, Seagen <b>Honoraria:</b> Aptitude Health, Curio Science, Physicians' Education Resource, Plexus Communications <b>Membership on a Board or Advisory Committee:</b> Karyopharm <b>Research Funding:</b> Constellation, Genentech, Karyopharm
Bethany Samuelson Bannow, MD, MCR	A Day in the Life of a Shematologist: Exploring the Intersection of Hematology and Women's Health	January 10 - 11, 2025	Seattle, WA	Speaker	<b>Membership on a Board or Advisory Committee:</b> Hema Biologics
Bart L. Scott, MD	Classical Insights in Transplantation	January 10 - 11, 2025 January 31 - February 1, 2025	Seattle, WA Washington, DC	Speaker	<b>Consultancy:</b> Agios, Celgene, Jazz, Taiho Oncology <b>Honoraria:</b> Agios, Alexion, BMS, Celgene, Geron <b>Speakers Bureau:</b> Agios, Alexion, BMS, Celgene, Geron, Incyte, Novartis, Taiho Oncology <b>Research Funding:</b> Incyte, Jazz, Novartis
Joseph Shatzel, MD, MCR	Consultative Hematology: What Are My Other Options?	January 10 - 11, 2025 January 31 - February 1, 2025	Seattle, WA Washington, DC	Speaker	Nothing to disclose.
Melody Smith, MD, MS	Classical Insights in Transplantation	January 17- 18, 2025	Chicago, IL	Speaker	<b>Consultancy:</b> A28 Therapeutics <b>Membership on a Board or Advisory Committee:</b> CVS Caremark
Deborah Stephens, DO	The Evolving Role of Targeted and Immunotherapy in Indolent Lymphoma and Chronic Lymphocytic Leukemia	January 17- 18, 2025	Chicago, IL	Speaker	<b>Consultancy:</b> AbbVie, AstraZeneca, Beigene, BMS, Celgene, Eli Lilly, Genentech, Janssen, Pharmacyclics, TG Therapeutics <b>Research Funding:</b> AstraZeneca, BMS, Genetech, Novartis
Douglas Tremblay, MD	Moving the Needle in the Treatment of Myeloproliferative Neoplasms and Chronic Myeloid Leukemia	January 10 - 11, 2025	New York, NY	Speaker	<b>Consultancy:</b> AbbVie, Cogent Biosciences, Novartis, PharmaEssentia, Sierra Oncology, Sobi <b>Research Funding:</b> Cogent Biosciences, Geron, Gilead, Sobi, Sumitomo
Eric Tse, PhD, MBBS	N/A	N/A	N/A	Planner	<b>Consultancy:</b> Merck Sharp & Dohme <b>Honoraria:</b> AbbVie, Beigene, Merck Sharp & Dohme, Roche
Michelle Zeller, MD, MHPE, FRCPC, DRCPSC	Transfusion Medicine	January 10 - 11, 2025	New York, NY	Planner/Speaker	<b>Membership on a Board or Advisory Committee:</b> Pfizer <b>Research Funding:</b> Pfizer Global Research Grant
Ayesha Zia, MD, MSCS	Inherited Disorders of Coagulation	January 31 - February 1, 2025	Washington, DC	Speaker	<b>Membership on a Board or Advisory Committee:</b> Hema Biologics, Sanofi, Star Therapeutics

All relevant financial relationships have been mitigated.

Staff planners have nothing to disclose.